CURRENT REPORT 7/2025
March 26, 2025

Preclinical data on Synthetic Lethality Programs to be presented at the 2025 AACR Annual Meeting

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") announces that the Company will present preclinical data from its' Synthetic Lethality Platform and PRMT5 project at the AACR 2025 Annual Meeting, which will take place on April 23-30, 2025, in Chicago, United States.

Details on the abstract presentations are as follows:

Abstract Title: "Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment"
Session Name: HDAC and Methyltransferase Inhibitors
Session date and time: Tuesday, April 29, 9:00 AM - 12:00 PM EST
Poster Number: 17 (board number), abstract number 4231

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant potential in targeting MTAP-deleted cancers. In preclinical studies, RVU305 effectively inhibited tumor growth in MTAP-null cancer models without affecting normal cells. Co-treatment with an anti-PD-1 antibody was well tolerated and resulted in antitumor activity in an MTAP-deleted, immune checkpoint inhibitors resistant model. The effects of RVU305, both alone and in combination with anti-PD-1, were supported by pharmacodynamic changes observed in tumor tissue. These results position RVU305 as a promising therapeutic option for patients carrying MTAP-deleted cancers resistant to immune checkpoint inhibitors treatment.

Abstract Title: "Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies"
Session Name: Experimental and Molecular Therapeutics
Session date and time: Monday, April 28, 2:00 PM - 5:00 PM EST
Poster Number: 3 (board number), abstract number 2973

This study highlights the discovery and validation of novel therapeutic targets for colorectal cancer (CRC) through synthetic lethal (SL) interactions, aiming to address the urgent need for more effective treatments. By using advanced models, including genetically engineered human intestinal stem cells (hISCs) and patient-derived xenografts (PDXs), combined with CRISPR/Cas9 technology, the team identified key vulnerabilities in

CRC cells. Genome-wide screens revealed SL targets, particularly in genes associated with APC and KRAS mutations. These findings were validated both in vitro and in vivo, paving the way for the development of new, targeted therapies for CRC patients based on their unique mutational profiles.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board